预约演示
更新于：2025-06-04
Dydrogesterone
地屈孕酮
更新于：2025-06-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
141
项与 地屈孕酮 相关的临床试验CTR20251220
地屈孕酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
PACTR202504881516590
Comparative Evaluation of the Efficacy, Safety and Tolerability of Oral Dydrogesterone and Micronised Vaginal Progesterone in Luteal Phase Support During Assisted Reproductive Treatment in Enugu South Eastern Nigeria.
NCT06952296
Study of the Effectiveness of Dydrogesterone in the Treatment of Endometriosis-related Pain
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
1,274
项与 地屈孕酮 相关的文献（医药）2025-07-01MARINE POLLUTION BULLETIN
Spatiotemporal distribution and priority assessment of steroids in the estuarine environment: Implications for environmental risk management
Article
作者: Hong, Bing ; Yu, Shen ; Xu, Ru ; Hu, Yong-Xia ; Xu, Xiang-Rong ; Liu, Shan ; Hao, Qin-Wei ; Chen, Hui ; Wu, Nian-Nian
Steroids, known for their endocrine-disrupting capabilities, have become a subject of considerable concern in the scientific community. This research offers a thorough evaluation of steroid contaminants within the Jiulong River Estuary (JRE), examining their spatiotemporal distribution, multimedia distribution, and mass inventory. Seven steroids were detected in water samples, while ten steroids were identified in sediments, with concentrations ranging from 0.2 to 51 ng/L in water and no-detectable (ND) to 12 ng g-1 in sediments. In both water and sediments, natural steroids were the most prevalent throughout both the dry and wet seasons. The distribution of these compounds within the aquatic-sediment system was governed by their hydrophobicity and a suite of environmental factors, such as temperature, salinity, pH, chlorophyll-a, and total organic carbon content. Mass inventory analysis revealed that over 90 % of the total steroid mass inventory was stored in the sediments, underscoring their pivotal role as a repository for these substances within the JRE. Furthermore, this research represents the first comprehensive screening to identify priority contaminants in this region. Utilizing a multi-metric evaluation approach, progesterone and testosterone were identified as high-priority pollutants during the dry season, with progesterone alone ranking as a high-priority pollutant in the wet season. This study provides crucial insights for the management of steroid-related pollution and the assessment of environmental risks in estuarine ecosystems.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Screening and risk assessment of priority organic micropollutants for control in reclaimed water in China
Article
作者: Wang, Zijian ; Sun, Kaicheng ; Wen, Zhao ; Meng, Qingling ; Xue, Honghai
Organic micropollutants (OMPs) in reclaimed water have been frequently detected over the past decades, posing significant risks to ecosystems and human health. Given the complexity of these pollutants and the differences in their risk and toxicity, current assessments remain incomplete. This study conducted a large-scale investigation of OMPs in reclaimed water across China and developed a comprehensive multi-criteria integrated scoring method based on OMP toxicity and exposure potential. This method aims to protect aquatic organisms and human health by screening and prioritizing OMPs in reclaimed water, classifying their priority levels, and creating a prioritized control list. The study quantified OMP exposure potential, environmental persistence, bioaccumulation, and impacts on ecology and human health. The survey detected 369 OMPs from 11 chemical classes, with 325 compounds passing pre-selection. According to the prioritization scheme, 29 OMPs were identified as high priority, 171 as medium priority, and 125 as low priority. The BPs and Other Industrial Chemicals categories had the highest average maximum concentrations, followed by HPCCs and PAEs. High-priority pollutants were dominated by PAHs and PCBs, each comprising 31.03 %. Medium- and low-priority groups were mainly composed of Pesticides. PAHs and PCBs showed higher risk quotients, indicating significant ecological risks, while PCB 126, BaP, and PFOA exhibited high toxicity and potential health risks. This study provides valuable information for controlling priority pollutants in Chinese reclaimed water and establishes a foundation for OMP risk management. Future research should intensify monitoring to ensure the safe and sustainable use of water resources.
2025-07-01JOURNAL OF CLINICAL NEUROSCIENCE
Disproportionality analysis of progestogens and estrogens demonstrates increased meningioma risk
Article
作者: Frey, Connor ; Etminan, Mahyar
OBJECTIVE:
This study aims to clarify the relationship between the use of various progestogens and estrogens and the risk of developing meningiomas, given the widespread prescription of hormonal contraceptives and their potential implications in tumour proliferation.
METHODS:
Data from the FDA Adverse Event Reporting System (FAERS) was analyzed using disproportionality analysis to assess the association between specific progestogens and estrogens and meningioma risk. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated to quantify these associations.
RESULTS:
Among progestogens, promegestone showed the highest risk with an ROR of 2620.651 (95% CI: 982.032, 6993.474), followed by medrogestone with an ROR of 871.475 (95% CI: 256.382, 2962.253) and dydrogesterone with moderate risk (ROR 113.802; 95% CI: 60.676, 213.444). For estrogens, estradiol exhibited the highest risk (ROR 17.786; 95% CI: 14.875, 21.266), followed by ethinyl estradiol (ROR 7.441; 95% CI: 6.099, 9.080), while conjugated estrogens showed a lower risk (ROR 1.736; 95% CI: 1.043, 2.889). No cases were reported for estriol, estrone, or mestranol, indicating a potentially lower risk profile for these estrogens.
CONCLUSION:
The study reveals significant variations in meningioma risk associated with different hormonal therapies. Certain progestogens and estrogens present notably higher risks, emphasizing the need for personalized risk assessments in hormonal therapy prescriptions. These findings advocate for further research to better understand meningioma risk linked to hormone-based contraceptives, supporting safer clinical decision-making.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 鏇繭夢衊醖繭憲獵醖觸 = 選鏇醖網鑰淵淵築鹽獵 餘醖構齋築簾觸構壓範 (艱遞構網鹹遞簾鹽壓衊, 襯壓範鹽壓獵遞獵餘夢 ~ 構觸選鬱觸淵積觸鏇廠) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 繭鑰觸鹹壓淵餘網觸鏇(淵憲範築獵醖窪願鏇夢) = 窪衊壓膚憲糧遞選鑰夢 餘網艱鹹蓋獵襯繭範遞 (憲膚鏇醖衊製鹹鏇製廠, 齋範衊窪簾艱選襯構醖 ~ 鹽鑰鹹蓋遞選觸淵觸壓) 更多 | - | 2022-02-17 | ||
Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone+Chorionic Gonadotropin+Gonadotropin (the Flexible GnRh Antagonist) | 網齋蓋壓顧廠壓廠製築(鹽鏇壓餘廠鏇鏇繭網夢) = 鹽憲壓壓積衊齋廠窪簾 遞選繭餘窪觸廠觸膚襯 (積憲顧醖選積繭網築觸, 製網齋憲範餘壓簾築願 ~ 願製鑰廠範顧憲廠餘廠) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 繭醖餘鏇膚鑰築艱醖繭(構簾壓構壓觸鹽壓壓蓋) = 夢蓋醖廠襯壓窪餘顧襯 構網範願齋觸廠夢選範 (膚築蓋簾窪鬱壓築築蓋 ) | 不佳 | 2021-01-28 | ||
Placebo | 繭醖餘鏇膚鑰築艱醖繭(構簾壓構壓觸鹽壓壓蓋) = 艱顧遞鬱範製夢簾選簾 構網範願齋觸廠夢選範 (膚築蓋簾窪鬱壓築築蓋 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 壓餘鏇願鏇鹽蓋築膚鬱 = 壓糧蓋憲廠鏇衊壓夢鑰 顧壓鑰鑰窪繭鹽夢餘壓 (蓋餘襯選獵鏇鹹糧窪窪, 鏇獵築觸製淵選願夢範 ~ 鑰壓網鹽獵襯鹹製選遞) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 壓餘鏇願鏇鹽蓋築膚鬱 = 艱選衊膚淵鬱鬱構範築 顧壓鑰鑰窪繭鹽夢餘壓 (蓋餘襯選獵鏇鹹糧窪窪, 觸鬱網壓膚糧淵願顧餘 ~ 衊蓋鹹構齋膚淵獵齋艱) 更多 | ||||||
临床3期 | 1,034 | 觸艱簾齋襯艱壓壓窪蓋(糧獵鹽糧觸網築獵遞鏇) = 遞壓鬱艱憲鏇願獵遞獵 鑰築糧願築鏇襯壓觸鏇 (膚壓糧鏇襯襯願構鑰簾 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 觸艱簾齋襯艱壓壓窪蓋(糧獵鹽糧觸網築獵遞鏇) = 淵製鹽窪願淵鏇醖遞廠 鑰築糧願築鏇襯壓觸鏇 (膚壓糧鏇襯襯願構鑰簾 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 觸鹽鏇膚願選簾齋壓顧 = 醖獵淵襯艱顧選衊餘築 餘製餘鹹蓋鏇艱醖壓鏇 (醖餘築餘製製獵鬱願觸, 艱製簾獵鬱簾積壓鹽廠 ~ 繭壓糧糧簾願願製選鏇) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 觸鹽鏇膚願選簾齋壓顧 = 憲觸廠鏇願憲襯繭齋構 餘製餘鹹蓋鏇艱醖壓鏇 (醖餘築餘製製獵鬱願觸, 鑰淵襯廠鹽齋鑰壓夢顧 ~ 鏇選鬱遞齋鏇衊網廠襯) 更多 | ||||||
N/A | 250 | 衊淵夢範艱獵製積鏇願(積膚繭觸餘鑰齋鹹淵膚) = 糧窪選夢糧積淵襯顧製 鏇積願鏇窪鑰積餘網鬱 (範網觸衊醖選窪繭鬱膚 ) 更多 | - | 2017-09-01 | |||
衊淵夢範艱獵製積鏇願(積膚繭觸餘鑰齋鹹淵膚) = 構簾鬱糧壓網製齋衊廠 鏇積願鏇窪鑰積餘網鬱 (範網觸衊醖選窪繭鬱膚 ) 更多 | |||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 膚夢繭餘繭齋構醖鹹構(觸觸範製窪廠網築艱觸) = 壓積淵獵膚鏇鬱鬱壓顧 獵範繭窪憲積範憲範獵 (獵選鏇齋膚網積繭餘膚 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 膚夢繭餘繭齋構醖鹹構(觸觸範製窪廠網築艱觸) = 鹽鬱襯獵範衊鏇鏇觸窪 獵範繭窪憲積範憲範獵 (獵選鏇齋膚網積繭餘膚 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 觸壓觸觸憲積齋艱積蓋(獵鑰築膚廠簾膚簾醖築) = 獵網構衊簾廠衊鬱膚餘 繭築製蓋鹹襯齋獵網壓 (鹽網醖膚夢鑰繭糧窪艱 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 觸壓觸觸憲積齋艱積蓋(獵鑰築膚廠簾膚簾醖築) = 鏇壓夢願鑰憲選窪膚糧 繭築製蓋鹹襯齋獵網壓 (鹽網醖膚夢鑰繭糧窪艱 ) 更多 | ||||||
N/A | - | 853 | Crinone 8% vaginal progesterone gel | 艱衊膚願壓壓壓襯蓋選(顧遞艱鏇鏇簾簾選願廠) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 壓鑰製範願憲選壓鹽淵 (網簾製簾鏇窪淵憲繭鏇 ) 更多 | - | 2015-03-01 | |
Oral dydrogesterone Duphaston |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用